Collegium Pharmaceutical, Inc.
COLLNASDAQHealthcare● Active
$33.50
+$0.12(+0.37%)
Market Cap$1.1B
P/E Ratio—
52W High$50.787
52W Low$29.08
Collegium Pharmaceutical, Inc. (COLL) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
COLL · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
$1.76
Est. $1.52 · +15.8%
Revenue
$0.19B
Est. $0.18B · +4.9%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 1-Quarter EPS Beat Streak
COLL reports quarterly as a NASDAQ-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | $1.68 | — | — | — | $0.20B | — |
| ▲ Q2 FY2026 | May 7, 2026 | $1.52 | $1.76 | +15.8% | $0.19B | $0.18B | +4.9% |
| ▼ Q1 FY2026 | Feb 26, 2026 | $2.14 | $2.04 | -4.7% | $0.21B | $0.21B | -0.4% |
| ▲ Q4 FY2025 | Nov 6, 2025 | $1.86 | $2.25 | +21.0% | $0.21B | $0.21B | +1.6% |
| ▲ Q3 FY2025 | Aug 7, 2025 | $1.62 | $1.68 | +3.7% | $0.19B | $0.19B | -1.7% |
| ▲ Q2 FY2025 | May 8, 2025 | $1.43 | $1.49 | +4.2% | $0.18B | $0.17B | +2.7% |
| ▲ Q1 FY2025 | Feb 27, 2025 | $1.54 | $1.77 | +14.9% | $0.18B | $0.18B | +1.3% |
| ▲ Q4 FY2024 | Nov 7, 2024 | $1.59 | $1.61 | +1.3% | $0.16B | $0.18B | -11.3% |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
$1.68
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Beat
EPS Actual
$1.76
EPS Est.
$1.52
EPS Surpr.
+15.8%
Revenue
$0.19B
Q1 FY2026
Feb 26, 2026Miss
EPS Actual
$2.04
EPS Est.
$2.14
EPS Surpr.
-4.7%
Revenue
$0.21B
Q4 FY2025
Nov 6, 2025Beat
EPS Actual
$2.25
EPS Est.
$1.86
EPS Surpr.
+21.0%
Revenue
$0.21B
Q3 FY2025
Aug 7, 2025Beat
EPS Actual
$1.68
EPS Est.
$1.62
EPS Surpr.
+3.7%
Revenue
$0.19B
Q2 FY2025
May 8, 2025Beat
EPS Actual
$1.49
EPS Est.
$1.43
EPS Surpr.
+4.2%
Revenue
$0.18B
Q1 FY2025
Feb 27, 2025Beat
EPS Actual
$1.77
EPS Est.
$1.54
EPS Surpr.
+14.9%
Revenue
$0.18B
Q4 FY2024
Nov 7, 2024Beat
EPS Actual
$1.61
EPS Est.
$1.59
EPS Surpr.
+1.3%
Revenue
$0.16B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $2.12 | $2.20 | $2.27 | 1 |
| Q3 FY2027 | $2.00 | $2.08 | $2.14 | 1 |
| Q2 FY2027 | $1.84 | $1.90 | $1.96 | 1 |
| Q1 FY2027 | $1.65 | $1.71 | $1.77 | 1 |
| Q4 FY2026 | $2.13 | $2.20 | $2.27 | 1 |
| Q3 FY2026 | $1.97 | $2.08 | $2.18 | 3 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.3B | $0.3B | $0.3B | 1 |
| Q3 FY2027 | $0.2B | $0.3B | $0.3B | 2 |
| Q2 FY2027 | $0.2B | $0.2B | $0.2B | 2 |
| Q1 FY2027 | $0.2B | $0.2B | $0.2B | 1 |
| Q4 FY2026 | $0.2B | $0.2B | $0.3B | 2 |
| Q3 FY2026 | $0.2B | $0.2B | $0.2B | 3 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 7, 2026 | +15.8% | $36.51 | $39.33 | +7.72% |
| ▼ Q1 FY2026 | Feb 26, 2026 | -4.7% | $45.75 | $44.22 | -3.34% |
| ▲ Q4 FY2025 | Nov 6, 2025 | +21.0% | $35.85 | $40.66 | +13.42% |
| ▲ Q3 FY2025 | Aug 7, 2025 | +3.7% | $29.75 | $32.94 | +10.72% |
| ▲ Q2 FY2025 | May 8, 2025 | +4.2% | $27.05 | $27.27 | +0.81% |
| ▲ Q1 FY2025 | Feb 27, 2025 | +14.9% | $28.35 | $28.42 | +0.25% |
| ▲ Q4 FY2024 | Nov 7, 2024 | +1.3% | $34.50 | $34.71 | +0.61% |
| ▲ Q3 FY2024 | Aug 8, 2024 | +8.7% | $34.65 | $35.32 | +1.93% |
Q2 FY2026+7.72%
Report Date
May 7, 2026
EPS Beat/Miss
+15.8%
Price Before
$36.51
Price After
$39.33
Q1 FY2026-3.34%
Report Date
Feb 26, 2026
EPS Beat/Miss
-4.7%
Price Before
$45.75
Price After
$44.22
Q4 FY2025+13.42%
Report Date
Nov 6, 2025
EPS Beat/Miss
+21.0%
Price Before
$35.85
Price After
$40.66
Q3 FY2025+10.72%
Report Date
Aug 7, 2025
EPS Beat/Miss
+3.7%
Price Before
$29.75
Price After
$32.94
Q2 FY2025+0.81%
Report Date
May 8, 2025
EPS Beat/Miss
+4.2%
Price Before
$27.05
Price After
$27.27
Q1 FY2025+0.25%
Report Date
Feb 27, 2025
EPS Beat/Miss
+14.9%
Price Before
$28.35
Price After
$28.42
Q4 FY2024+0.61%
Report Date
Nov 7, 2024
EPS Beat/Miss
+1.3%
Price Before
$34.50
Price After
$34.71
Q3 FY2024+1.93%
Report Date
Aug 8, 2024
EPS Beat/Miss
+8.7%
Price Before
$34.65
Price After
$35.32
Avg Beat Reaction+5.07%
Avg Miss Reaction-3.34%
Beat Rate7 / 8 quarters
Largest Move+13.42% (Q4 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: COLL ends December
Collegium Pharmaceutical, Inc. (COLL) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $1.76 — beating the analyst consensus of $1.52 by +15.8%. The next COLL earnings date is expected around September 1, 2026.
Each quarter, investors track COLL earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. COLL revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
COLL's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
COLL earnings · 5 questionsCollegium Pharmaceutical, Inc.'s next earnings report is expected around September 1, 2026. COLL typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; COLL historically reports after market close (AMC).
COLL earnings datewhen is COLL earningsCOLL next earnings datewhen does COLL report earningsCOLL earnings calendar
▸ Source: FMP · Collegium Pharmaceutical, Inc. SEC filings · US GAAP · Collegium Pharmaceutical, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026